Acceleron Pharma Inc (XLRN)

34.10
0.15 0.44
NASDAQ : Health Care
Prev Close 33.95
Open 33.70
Day Low/High 32.60 / 34.43
52 Wk Low/High 20.00 / 50.86
Volume 862.82K
Avg Volume 375.60K
Exchange NASDAQ
Shares Outstanding 38.62M
Market Cap 1.25B
EPS -1.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Biotech Movers: Acceleron, Clovis, Coherus

Biotech Movers: Acceleron, Clovis, Coherus

Acceleron Pharma, Clovis Oncology and Coherus BioSciences premarket trading on Tuesday.

Acceleron Announces Top-Line Results From DART Phase 2 Study Of Dalantercept In Advanced Renal Cell Carcinoma

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that...

Celgene And Acceleron Complete Target Enrollment In The MEDALIST And BELIEVE Phase 3 Studies Of Luspatercept In Myelodysplastic Syndromes And Beta-Thalassemia

Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that they have completed target enrollment in the MEDALIST and BELIEVE Phase 3 studies of luspatercept in patients with...

Acceleron To Participate In Two Healthcare Investor Conferences In June

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that...

Acceleron Announces Clinical Presentations On Luspatercept At The 22nd Congress Of The European Hematology Association

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that...

Acceleron Pharma Reports First Quarter 2017 Operational And Financial Results

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today provided a...

Luspatercept Phase 2 Data Presented At The 14th International Symposium On Myelodysplastic Syndromes

Acceleron Pharma Inc. (NASDAQ:XLRN) and Celgene Corporation (NASDAQ:CELG), today announced preliminary Phase 2 results from the ongoing three-month base and long-term extension studies with investigational drug luspatercept...

Acceleron Announces Management Change

Acceleron Pharma Inc. (NASDAQ: XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced...

Leading Protein Scientist Dr. Asya Grinberg Joins Dragonfly Therapeutics As Head Of Biologics

Dr. Grinberg, senior scientist with 12 years of biotech industry experience in biologics discovery and development, joins Dragonfly's team to accelerate development of its novel Natural Killer cell-based immunotherapies.

Acceleron To Participate In Two Healthcare Investor Conferences In May

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that...

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.

Acceleron Provides Clinical Development Updates On Luspatercept Program

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced...

Acceleron To Host Webcast To Review First Quarter 2017 Financial And Operational Results On May 8, 2017

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that...

Acceleron Announces Clinical Presentations On Luspatercept At The 14th International Symposium On Myelodysplastic Syndromes

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that...

Acceleron Announces Plans To Initiate A Phase 2 Trial Of ACE-083 In Charcot-Marie-Tooth Neuromuscular Disease And Host Educational Webinar

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that...

Acceleron Pharma Price Target Raised by Leerink

Acceleron Pharma Price Target Raised by Leerink

The company reported a fourth quarter loss on Wednesday.

Acceleron Reports Fourth Quarter And Year Ended 2016 Operational And Financial Results

Acceleron Pharma Inc. (NASDAQ: XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today provided a...

Acceleron To Participate In Two Healthcare Investor Conferences In March

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that...

Acceleron Pharma To Webcast Conference Call Of Fourth Quarter And Year Ended 2016 Financial Results On March 1, 2017

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that...

Acceleron To Participate In Two Healthcare Investor Conferences In February

Acceleron Pharma Inc. (NASDAQ: XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced...

Acceleron Pharma Enters Oversold Territory (XLRN)

Acceleron Pharma Enters Oversold Territory (XLRN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Acceleron Outlines Corporate Goals And Priorities For 2017

Acceleron Outlines Corporate Goals And Priorities For 2017

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced its...

Acceleron To Webcast Presentation At 35th Annual J.P. Morgan Healthcare Conference

Acceleron To Webcast Presentation At 35th Annual J.P. Morgan Healthcare Conference

Acceleron Pharma Inc. (NASDAQ:XLRN) a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that...

Acceleron Announces First Patient Treated In Phase 2 Trial Of ACE-083 In Facioscapulohumeral Muscular Dystrophy

Acceleron Announces First Patient Treated In Phase 2 Trial Of ACE-083 In Facioscapulohumeral Muscular Dystrophy

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that...

Trump's Drug Pricing Comment Sends Biotech Stocks Into Free-Fall

Trump's Drug Pricing Comment Sends Biotech Stocks Into Free-Fall

There's little to substantiate the president-elect's claim that he will bring drug prices down, but biotech investors are trading anyway.

Acceleron And Celgene Announce Updated Results From Phase 2 Studies Of Luspatercept In Beta-Thalassemia Presented At The 58th Annual Meeting Of The American Society Of Hematology

Acceleron And Celgene Announce Updated Results From Phase 2 Studies Of Luspatercept In Beta-Thalassemia Presented At The 58th Annual Meeting Of The American Society Of Hematology

Acceleron Pharma Inc. (NASDAQ: XLRN) and Celgene Corporation (NASDAQ: CELG) today announced Phase 2 results from an open-label three-month base study and the ongoing long-term safety extension study with luspatercept in...

Blood Work: A Few Biotech Thoughts From Sunny San Diego and the ASH 2016 Meeting

Blood Work: A Few Biotech Thoughts From Sunny San Diego and the ASH 2016 Meeting

I spent the weekend with thousands of blood disease researchers. This is what happened.

Acceleron And Celgene Announce Preliminary Results From An Investigator Initiated Phase 2 Study Of Sotatercept In Myelofibrosis At The 58th Annual Meeting Of The American Society Of Hematology

Acceleron And Celgene Announce Preliminary Results From An Investigator Initiated Phase 2 Study Of Sotatercept In Myelofibrosis At The 58th Annual Meeting Of The American Society Of Hematology

Acceleron Pharma Inc. (NASDAQ:XLRN) and Celgene Corporation (NASDAQ:CELG), today announced preliminary results from an ongoing investigator initiated Phase 2 study with investigational drug sotatercept in patients with...